-
1
-
-
77950387206
-
Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come.
-
Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol 2010, 63:288-295.
-
(2010)
J Clin Pathol
, vol.63
, pp. 288-295
-
-
Ford, L.T.1
Berg, J.D.2
-
2
-
-
79951809968
-
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
-
Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011, 89:387-391.
-
(2011)
Clin Pharmacol Ther
, vol.89
, pp. 387-391
-
-
Relling, M.V.1
Gardner, E.E.2
Sandborn, W.J.3
Schmiegelow, K.4
Pui, C.H.5
Yee, S.W.6
Stein, C.M.7
Carrillo, M.8
Evans, W.E.9
Klein, T.E.10
-
3
-
-
38949196447
-
HLA-B*5701 screening for hypersensitivity to abacavir.
-
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
-
(2008)
N Engl J Med
, vol.358
, pp. 568-579
-
-
Mallal, S.1
Phillips, E.2
Carosi, G.3
Molina, J.M.4
Workman, C.5
Tomazic, J.6
Jägel-Guedes, E.7
Rugina, S.8
Kozyrev, O.9
Cid, J.F.10
Hay, P.11
Nolan, D.12
Hughes, S.13
Hughes, A.14
Ryan, S.15
Fitch, N.16
Thorborn, D.17
Benbow, A.18
-
4
-
-
2342624080
-
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
-
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Jänne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
Eck, M.J.14
Sellers, W.R.15
Johnson, B.E.16
Meyerson, M.17
-
5
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
6
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
7
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
-
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
Dummer, R.7
Garbe, C.8
Testori, A.9
Maio, M.10
Hogg, D.11
Lorigan, P.12
Lebbe, C.13
Jouary, T.14
Schadendorf, D.15
Ribas, A.16
O'Day, S.J.17
Sosman, J.A.18
Kirkwood, J.M.19
Eggermont, A.M.20
Dreno, B.21
Nolop, K.22
Li, J.23
Nelson, B.24
Hou, J.25
Lee, R.J.26
Flaherty, K.T.27
McArthur, G.A.28
more..
-
8
-
-
77953308585
-
The long and winding road to warfarin pharmacogenetic testing.
-
Ginsburg GS, Voora D. The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol 2010, 55:2813-2815.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 2813-2815
-
-
Ginsburg, G.S.1
Voora, D.2
-
9
-
-
60849097257
-
Estimation of the warfarin dose with clinical and pharmacogenetic data.
-
Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360:753-764.
-
(2009)
N Engl J Med
, vol.360
, pp. 753-764
-
-
Klein, T.E.1
Altman, R.B.2
Eriksson, N.3
Gage, B.F.4
Kimmel, S.E.5
Lee, M.T.6
Limdi, N.A.7
Page, D.8
Roden, D.M.9
Wagner, M.J.10
Caldwell, M.D.11
Johnson, J.A.12
-
11
-
-
58749094444
-
Cytochrome p-450 polymorphisms and response to clopidogrel.
-
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
-
(2009)
N Engl J Med
, vol.360
, pp. 354-362
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
Shen, L.4
Hockett, R.D.5
Brandt, J.T.6
Walker, J.R.7
Antman, E.M.8
Macias, W.9
Braunwald, E.10
Sabatine, M.S.11
-
12
-
-
78049433100
-
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
-
Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010, 363:1704-1714.
-
(2010)
N Engl J Med
, vol.363
, pp. 1704-1714
-
-
Pare, G.1
Mehta, S.R.2
Yusuf, S.3
Anand, S.S.4
Connolly, S.J.5
Hirsh, J.6
Simonsen, K.7
Bhatt, D.L.8
Fox, K.A.9
Eikelboom, J.W.10
-
13
-
-
78049326068
-
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
-
Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010, 304:1821-1830.
-
(2010)
JAMA
, vol.304
, pp. 1821-1830
-
-
Mega, J.L.1
Simon, T.2
Collet, J.P.3
Anderson, J.L.4
Antman, E.M.5
Bliden, K.6
Cannon, C.P.7
Danchin, N.8
Giusti, B.9
Gurbel, P.10
Horne, B.D.11
Hulot, J.S.12
Kastrati, A.13
Montalescot, G.14
Neumann, F.J.15
Shen, L.16
Sibbing, D.17
Steg, P.G.18
Trenk, D.19
Wiviott, S.D.20
Sabatine, M.S.21
more..
-
14
-
-
77955413903
-
Responding to the clopidogrel warning by the US Food and Drug Administration: real life is complicated.
-
Roden DM, Shuldiner AR. Responding to the clopidogrel warning by the US Food and Drug Administration: real life is complicated. Circulation 2010, 122:445-448.
-
(2010)
Circulation
, vol.122
, pp. 445-448
-
-
Roden, D.M.1
Shuldiner, A.R.2
-
15
-
-
0035856943
-
Diabetes mellitus and genetically programmed defects in beta-cell function.
-
Bell G, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001, 414:788-791.
-
(2001)
Nature
, vol.414
, pp. 788-791
-
-
Bell, G.1
Polonsky, K.S.2
-
16
-
-
0142186278
-
Genetic cause of hyperglycaemia and response to treatment in diabetes.
-
Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003, 362:1275-1281.
-
(2003)
Lancet
, vol.362
, pp. 1275-1281
-
-
Pearson, E.R.1
Starkey, B.J.2
Powell, R.J.3
Gribble, F.M.4
Clark, P.M.5
Hattersley, A.T.6
-
17
-
-
2342633204
-
Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
-
Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njølstad PR, Ashcroft FM, Hattersley AT. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004, 350:1838-1849.
-
(2004)
N Engl J Med
, vol.350
, pp. 1838-1849
-
-
Gloyn, A.L.1
Pearson, E.R.2
Antcliff, J.F.3
Proks, P.4
Bruining, G.J.5
Slingerland, A.S.6
Howard, N.7
Srinivasan, S.8
Silva, J.M.9
Molnes, J.10
Edghill, E.L.11
Frayling, T.M.12
Temple, I.K.13
Mackay, D.14
Shield, J.P.15
Sumnik, Z.16
van Rhijn, A.17
Wales, J.K.18
Clark, P.19
Gorman, S.20
Aisenberg, J.21
Ellard, S.22
Njølstad, P.R.23
Ashcroft, F.M.24
Hattersley, A.T.25
more..
-
18
-
-
4644260056
-
Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy.
-
Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, Abuelo D, Phornphutkul C, Molnes J, Bell GI, Gloyn AL, Hattersley AT, Molven A, Søvik O, Njølstad PR. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004, 53:2713-2718.
-
(2004)
Diabetes
, vol.53
, pp. 2713-2718
-
-
Sagen, J.V.1
Raeder, H.2
Hathout, E.3
Shehadeh, N.4
Gudmundsson, K.5
Baevre, H.6
Abuelo, D.7
Phornphutkul, C.8
Molnes, J.9
Bell, G.I.10
Gloyn, A.L.11
Hattersley, A.T.12
Molven, A.13
Søvik, O.14
Njølstad, P.R.15
-
19
-
-
33746686369
-
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
-
Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006, 355:467-477.
-
(2006)
N Engl J Med
, vol.355
, pp. 467-477
-
-
Pearson, E.R.1
Flechtner, I.2
Njølstad, P.R.3
Malecki, M.T.4
Flanagan, S.E.5
Larkin, B.6
Ashcroft, F.M.7
Klimes, I.8
Codner, E.9
Iotova, V.10
Slingerland, A.S.11
Shield, J.12
Robert, J.J.13
Holst, J.J.14
Clark, P.M.15
Ellard, S.16
Søvik, O.17
Polak, M.18
Hattersley, A.T.19
-
20
-
-
33746778878
-
Activating mutations in the ABCC8 gene in neonatal diabetes mellitus.
-
Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M, Froguel P. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006, 355:456-466.
-
(2006)
N Engl J Med
, vol.355
, pp. 456-466
-
-
Babenko, A.P.1
Polak, M.2
Cave, H.3
Busiah, K.4
Czernichow, P.5
Scharfmann, R.6
Bryan, J.7
Aguilar-Bryan, L.8
Vaxillaire, M.9
Froguel, P.10
-
21
-
-
78649842241
-
Genomics, type 2 diabetes, and obesity.
-
McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010, 363:2339-2350.
-
(2010)
N Engl J Med
, vol.363
, pp. 2339-2350
-
-
McCarthy, M.I.1
-
22
-
-
43249125992
-
Estimation of the multiple testing burden for genomewide association studies of nearly all common variants.
-
Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol 2008, 32:381-385.
-
(2008)
Genet Epidemiol
, vol.32
, pp. 381-385
-
-
Pe'er, I.1
Yelensky, R.2
Altshuler, D.3
Daly, M.J.4
-
23
-
-
78649468820
-
The genetics of type 2 diabetes: what have we learned from GWAS?
-
Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS?. Ann N Y Acad Sci 2010, 1212:59-77.
-
(2010)
Ann N Y Acad Sci
, vol.1212
, pp. 59-77
-
-
Billings, L.K.1
Florez, J.C.2
-
24
-
-
80051766486
-
Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.
-
Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011, 12:1161-1191.
-
(2011)
Pharmacogenomics
, vol.12
, pp. 1161-1191
-
-
Manolopoulos, V.G.1
Ragia, G.2
Tavridou, A.3
-
25
-
-
0036231580
-
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
-
Kirchheiner J, Brockm-Iller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002, 71:286-296.
-
(2002)
Clin Pharmacol Ther
, vol.71
, pp. 286-296
-
-
Kirchheiner, J.1
Brockm-Iller, J.2
Meineke, I.3
Bauer, S.4
Rohde, W.5
Meisel, C.6
Roots, I.7
-
26
-
-
2942620708
-
Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.
-
Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J, Walchner-Bonjean M, Hering U, Jakob V, Rodamer M, Jabrane W, Kasel D, Brockmöller J, Fuhr U, Sörgel F. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 2004, 60:165-171.
-
(2004)
Eur J Clin Pharmacol
, vol.60
, pp. 165-171
-
-
Jetter, A.1
Kinzig-Schippers, M.2
Skott, A.3
Lazar, A.4
Tomalik-Scharte, D.5
Kirchheiner, J.6
Walchner-Bonjean, M.7
Hering, U.8
Jakob, V.9
Rodamer, M.10
Jabrane, W.11
Kasel, D.12
Brockmöller, J.13
Fuhr, U.14
Sörgel, F.15
-
27
-
-
0036736497
-
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
-
Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivistö KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002, 72:326-332.
-
(2002)
Clin Pharmacol Ther
, vol.72
, pp. 326-332
-
-
Niemi, M.1
Cascorbi, I.2
Timm, R.3
Kroemer, H.K.4
Neuvonen, P.J.5
Kivistö, K.T.6
-
28
-
-
33646122444
-
Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
-
Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 2006, 72:148-154.
-
(2006)
Diabetes Res Clin Pract
, vol.72
, pp. 148-154
-
-
Suzuki, K.1
Yanagawa, T.2
Shibasaki, T.3
Kaniwa, N.4
Hasegawa, R.5
Tohkin, M.6
-
29
-
-
72849111539
-
Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
-
Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Lang CC, Palmer CN, Pearson ER. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 2010, 87:52-56.
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 52-56
-
-
Zhou, K.1
Donnelly, L.2
Burch, L.3
Tavendale, R.4
Doney, A.S.5
Leese, G.6
Hattersley, A.T.7
McCarthy, M.I.8
Morris, A.D.9
Lang, C.C.10
Palmer, C.N.11
Pearson, E.R.12
-
30
-
-
0035043009
-
Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53).
-
Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med 2001, 18:206-212.
-
(2001)
Diabet Med
, vol.18
, pp. 206-212
-
-
Gloyn, A.L.1
Hashim, Y.2
Ashcroft, S.J.3
Ashfield, R.4
Wiltshire, S.5
Turner, R.C.6
-
31
-
-
0037317981
-
Large-scale association studies of variants in genes encoding the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes.
-
Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G, Walker M, Levy JC, Sampson M, Halford S, McCarthy MI, Hattersley AT, Frayling TM. Large-scale association studies of variants in genes encoding the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003, 52:568-572.
-
(2003)
Diabetes
, vol.52
, pp. 568-572
-
-
Gloyn, A.L.1
Weedon, M.N.2
Owen, K.R.3
Turner, M.J.4
Knight, B.A.5
Hitman, G.6
Walker, M.7
Levy, J.C.8
Sampson, M.9
Halford, S.10
McCarthy, M.I.11
Hattersley, A.T.12
Frayling, T.M.13
-
32
-
-
4243062602
-
Candidate gene association study in type 2 diabetes indicates a role for genes involved in β-cell function as well as insulin action.
-
Barroso I, Luan J, Middelberg RPS, Harding A-H, Franks PW, Jakes RW, Clayton D, Schafer AJ, O'Rahilly S, Wareham NJ. Candidate gene association study in type 2 diabetes indicates a role for genes involved in β-cell function as well as insulin action. PLoS Biol 2003, 1:e20.
-
(2003)
PLoS Biol
, vol.1
-
-
Barroso, I.1
Luan, J.2
Middelberg, R.P.S.3
Harding, A.-H.4
Franks, P.W.5
Jakes, R.W.6
Clayton, D.7
Schafer, A.J.8
O'Rahilly, S.9
Wareham, N.J.10
-
33
-
-
2342561802
-
Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region.
-
Florez JC, Burtt N, de Bakker PI, Almgren P, Tuomi T, Holmkvist J, Gaudet D, Hudson TJ, Schaffner SF, Daly MJ, Hirschhorn JN, Groop L, Altshuler D. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004, 53:1360-1368.
-
(2004)
Diabetes
, vol.53
, pp. 1360-1368
-
-
Florez, J.C.1
Burtt, N.2
de Bakker, P.I.3
Almgren, P.4
Tuomi, T.5
Holmkvist, J.6
Gaudet, D.7
Hudson, T.J.8
Schaffner, S.F.9
Daly, M.J.10
Hirschhorn, J.N.11
Groop, L.12
Altshuler, D.13
-
34
-
-
15144338831
-
Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM.
-
Inoue H, Ferrer J, Warren-Perry M, Zhang Y, Millns H, Turner RC, Elbein SC, Hampe CL, Suarez BK, Inagaki N, Seino S, Permutt MA. Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. Diabetes 1997, 46:502-507.
-
(1997)
Diabetes
, vol.46
, pp. 502-507
-
-
Inoue, H.1
Ferrer, J.2
Warren-Perry, M.3
Zhang, Y.4
Millns, H.5
Turner, R.C.6
Elbein, S.C.7
Hampe, C.L.8
Suarez, B.K.9
Inagaki, N.10
Seino, S.11
Permutt, M.A.12
-
35
-
-
70349648967
-
Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel.
-
Hamming KS, Soliman D, Matemisz LC, Niazi O, Lang Y, Gloyn AL, Light PE. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes 2009, 58:2419-2424.
-
(2009)
Diabetes
, vol.58
, pp. 2419-2424
-
-
Hamming, K.S.1
Soliman, D.2
Matemisz, L.C.3
Niazi, O.4
Lang, Y.5
Gloyn, A.L.6
Light, P.E.7
-
36
-
-
33744965950
-
The E23K variant of KCNJ11 encoding the pancreatic b-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
-
Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, Gnasso A, Grupillo M, Lauro R, Hribal ML, Perticone F, Marchetti P. The E23K variant of KCNJ11 encoding the pancreatic b-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:2334-2339.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 2334-2339
-
-
Sesti, G.1
Laratta, E.2
Cardellini, M.3
Andreozzi, F.4
Del Guerra, S.5
Irace, C.6
Gnasso, A.7
Grupillo, M.8
Lauro, R.9
Hribal, M.L.10
Perticone, F.11
Marchetti, P.12
-
37
-
-
67949099109
-
The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
-
Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res 2009, 41:387-390.
-
(2009)
Horm Metab Res
, vol.41
, pp. 387-390
-
-
Holstein, A.1
Hahn, M.2
Stumvoll, M.3
Kovacs, P.4
-
38
-
-
56149106823
-
Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.
-
Feng Y, Mao G, Ren X, Xing H, Tang G, Li Q, Li X, Sun L, Yang J, Ma W, Wang X, Xu X. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008, 31:1939-1944.
-
(2008)
Diabetes Care
, vol.31
, pp. 1939-1944
-
-
Feng, Y.1
Mao, G.2
Ren, X.3
Xing, H.4
Tang, G.5
Li, Q.6
Li, X.7
Sun, L.8
Yang, J.9
Ma, W.10
Wang, X.11
Xu, X.12
-
39
-
-
32544451924
-
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes.
-
Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006, 38:320-323.
-
(2006)
Nat Genet
, vol.38
, pp. 320-323
-
-
Grant, S.F.1
Thorleifsson, G.2
Reynisdottir, I.3
Benediktsson, R.4
Manolescu, A.5
Sainz, J.6
Helgason, A.7
Stefansson, H.8
Emilsson, V.9
Helgadottir, A.10
Styrkarsdottir, U.11
Magnusson, K.P.12
Walters, G.B.13
Palsdottir, E.14
Jonsdottir, T.15
Gudmundsdottir, T.16
Gylfason, A.17
Saemundsdottir, J.18
Wilensky, R.L.19
Reilly, M.P.20
Rader, D.J.21
Bagger, Y.22
Christiansen, C.23
Gudnason, V.24
Sigurdsson, G.25
Thorsteinsdottir, U.26
Gulcher, J.R.27
Kong, A.28
Stefansson, K.29
more..
-
40
-
-
34447340935
-
TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis.
-
Cauchi S, El Achhab Y, Choquet H, Dina C, Krempler F, Weitgasser R, Nejjari C, Patsch W, Chikri M, Meyre D, Froguel P. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med 2007, 85:777-782.
-
(2007)
J Mol Med
, vol.85
, pp. 777-782
-
-
Cauchi, S.1
El Achhab, Y.2
Choquet, H.3
Dina, C.4
Krempler, F.5
Weitgasser, R.6
Nejjari, C.7
Patsch, W.8
Chikri, M.9
Meyre, D.10
Froguel, P.11
-
41
-
-
33846596193
-
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution.
-
Helgason A, Pálsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnarsdottir S, Adeyemo A, Chen Y, Chen G, Reynisdottir I, Benediktsson R, Hinney A, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Schäfer H, Faruque M, Doumatey A, Zhou J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Sigurdsson G, Hebebrand J, Pedersen O, Thorsteinsdottir U, Gulcher JR, et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 2007, 39:218-225.
-
(2007)
Nat Genet
, vol.39
, pp. 218-225
-
-
Helgason, A.1
Pálsson, S.2
Thorleifsson, G.3
Grant, S.F.4
Emilsson, V.5
Gunnarsdottir, S.6
Adeyemo, A.7
Chen, Y.8
Chen, G.9
Reynisdottir, I.10
Benediktsson, R.11
Hinney, A.12
Hansen, T.13
Andersen, G.14
Borch-Johnsen, K.15
Jorgensen, T.16
Schäfer, H.17
Faruque, M.18
Doumatey, A.19
Zhou, J.20
Wilensky, R.L.21
Reilly, M.P.22
Rader, D.J.23
Bagger, Y.24
Christiansen, C.25
Sigurdsson, G.26
Hebebrand, J.27
Pedersen, O.28
Thorsteinsdottir, U.29
Gulcher, J.R.30
more..
-
42
-
-
77649086970
-
A map of open chromatin in human pancreatic islets.
-
Gaulton KJ, Nammo T, Pasquali L, Simon JM, Giresi PG, Fogarty MP, Panhuis TM, Mieczkowski P, Secchi A, Bosco D, Berney T, Montanya E, Mohlke KL, Lieb JD, Ferrer J. A map of open chromatin in human pancreatic islets. Nat Genet 2010, 42:255-259.
-
(2010)
Nat Genet
, vol.42
, pp. 255-259
-
-
Gaulton, K.J.1
Nammo, T.2
Pasquali, L.3
Simon, J.M.4
Giresi, P.G.5
Fogarty, M.P.6
Panhuis, T.M.7
Mieczkowski, P.8
Secchi, A.9
Bosco, D.10
Berney, T.11
Montanya, E.12
Mohlke, K.L.13
Lieb, J.D.14
Ferrer, J.15
-
43
-
-
33746075560
-
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.
-
The diabetes Prevention Program Research Group
-
Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PIW, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D, . The diabetes Prevention Program Research Group TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006, 355:241-250. The diabetes Prevention Program Research Group.
-
(2006)
N Engl J Med
, vol.355
, pp. 241-250
-
-
Florez, J.C.1
Jablonski, K.A.2
Bayley, N.3
Pollin, T.I.4
de Bakker, P.I.W.5
Shuldiner, A.R.6
Knowler, W.C.7
Nathan, D.M.8
Altshuler, D.9
-
44
-
-
34547702501
-
Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.
-
Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, Sjögren M, Ling C, Eriksson KF, Lethagen AL, Mancarella R, Berglund G, Tuomi T, Nilsson P, Del Prato S, Groop L. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007, 117:2155-2163.
-
(2007)
J Clin Invest
, vol.117
, pp. 2155-2163
-
-
Lyssenko, V.1
Lupi, R.2
Marchetti, P.3
Del Guerra, S.4
Orho-Melander, M.5
Almgren, P.6
Sjögren, M.7
Ling, C.8
Eriksson, K.F.9
Lethagen, A.L.10
Mancarella, R.11
Berglund, G.12
Tuomi, T.13
Nilsson, P.14
Del Prato, S.15
Groop, L.16
-
45
-
-
34547585382
-
Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study.
-
Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney ASF, McCarthy MI, Hattersley AT, Morris AD, Palmer CNA. Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study. Diabetes 2007, 56:2178-2182.
-
(2007)
Diabetes
, vol.56
, pp. 2178-2182
-
-
Pearson, E.R.1
Donnelly, L.A.2
Kimber, C.3
Whitley, A.4
Doney, A.S.F.5
McCarthy, M.I.6
Hattersley, A.T.7
Morris, A.D.8
Palmer, C.N.A.9
-
46
-
-
79951960556
-
TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes.
-
Holstein A, Hahn M, Korner A, Stumvoll M, Kovacs P. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet 2011, 12:30.
-
(2011)
BMC Med Genet
, vol.12
, pp. 30
-
-
Holstein, A.1
Hahn, M.2
Korner, A.3
Stumvoll, M.4
Kovacs, P.5
-
47
-
-
78649693563
-
Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes.
-
Schroner Z, Javorsky M, Tkacova R, Klimcakova L, Dobrikova M, Habalova V, Kozarova M, Zidzik J, Rudikova M, Tkac I. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab 2011, 13:89-91.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 89-91
-
-
Schroner, Z.1
Javorsky, M.2
Tkacova, R.3
Klimcakova, L.4
Dobrikova, M.5
Habalova, V.6
Kozarova, M.7
Zidzik, J.8
Rudikova, M.9
Tkac, I.10
-
48
-
-
0029099086
-
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
-
DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995, 333:541-549.
-
(1995)
N Engl J Med
, vol.333
, pp. 541-549
-
-
DeFronzo, R.A.1
Goodman, A.M.2
-
49
-
-
0031472452
-
Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial.
-
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997, 103:491-497.
-
(1997)
Am J Med
, vol.103
, pp. 491-497
-
-
Garber, A.J.1
Duncan, T.G.2
Goodman, A.M.3
Mills, D.J.4
Rohlf, J.L.5
-
50
-
-
0032511566
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
-
UKPDS
-
UKPDS Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. UKPDS.
-
(1998)
Lancet
, vol.352
, pp. 854-865
-
-
-
51
-
-
33751159555
-
Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes.
-
Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006, 29:2361-2364.
-
(2006)
Diabetes Care
, vol.29
, pp. 2361-2364
-
-
Ong, C.R.1
Molyneaux, L.M.2
Constantino, M.I.3
Twigg, S.M.4
Yue, D.K.5
-
52
-
-
0029133235
-
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
-
Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333:550-554.
-
(1995)
N Engl J Med
, vol.333
, pp. 550-554
-
-
Stumvoll, M.1
Nurjhan, N.2
Perriello, G.3
Dailey, G.4
Gerich, J.E.5
-
53
-
-
0034773404
-
Role of AMP-activated protein kinase in mechanism of metformin action.
-
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174.
-
(2001)
J Clin Invest
, vol.108
, pp. 1167-1174
-
-
Zhou, G.1
Myers, R.2
Li, Y.3
Chen, Y.4
Shen, X.5
Fenyk-Melody, J.6
Wu, M.7
Ventre, J.8
Doebber, T.9
Fujii, N.10
Musi, N.11
Hirshman, M.F.12
Goodyear, L.J.13
Moller, D.E.14
-
54
-
-
0037067666
-
The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.
-
Fryer LGD, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002, 277:25226-25232.
-
(2002)
J Biol Chem
, vol.277
, pp. 25226-25232
-
-
Fryer, L.G.D.1
Parbu-Patel, A.2
Carling, D.3
-
55
-
-
77954933558
-
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.
-
Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010, 120:2355-2369.
-
(2010)
J Clin Invest
, vol.120
, pp. 2355-2369
-
-
Foretz, M.1
Hebrard, S.2
Leclerc, J.3
Zarrinpashneh, E.4
Soty, M.5
Mithieux, G.6
Sakamoto, K.7
Andreelli, F.8
Viollet, B.9
-
56
-
-
38349085099
-
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.
-
Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008, 83:273-280.
-
(2008)
Clin Pharmacol Ther
, vol.83
, pp. 273-280
-
-
Shu, Y.1
Brown, C.2
Castro, R.A.3
Shi, R.J.4
Lin, E.T.5
Owen, R.P.6
Sheardown, S.A.7
Yue, L.8
Burchard, E.G.9
Brett, C.M.10
Giacomini, K.M.11
-
57
-
-
77957238214
-
Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function.
-
Chen L, Takizawa M, Chen E, Schlessinger A, Segenthelar J, Choi JH, Sali A, Kubo M, Nakamura S, Iwamoto Y, Iwasaki N, Giacomini KM. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther 2010, 335:42-50.
-
(2010)
J Pharmacol Exp Ther
, vol.335
, pp. 42-50
-
-
Chen, L.1
Takizawa, M.2
Chen, E.3
Schlessinger, A.4
Segenthelar, J.5
Choi, J.H.6
Sali, A.7
Kubo, M.8
Nakamura, S.9
Iwamoto, Y.10
Iwasaki, N.11
Giacomini, K.M.12
-
58
-
-
66649121405
-
Reduced function SLC22A1 polymorphisms encoding Organic Cation Transporter 1 (OCT1) and glycaemic response to metformin: A Go-DARTS study.
-
Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Palmer CN, Pearson ER. Reduced function SLC22A1 polymorphisms encoding Organic Cation Transporter 1 (OCT1) and glycaemic response to metformin: A Go-DARTS study. Diabetes 2009, 58:1434-1439.
-
(2009)
Diabetes
, vol.58
, pp. 1434-1439
-
-
Zhou, K.1
Donnelly, L.A.2
Kimber, C.H.3
Donnan, P.T.4
Doney, A.S.5
Leese, G.6
Hattersley, A.T.7
McCarthy, M.I.8
Morris, A.D.9
Palmer, C.N.10
Pearson, E.R.11
-
59
-
-
67849116869
-
Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus.
-
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009, 9:242-247.
-
(2009)
Pharmacogenomics J
, vol.9
, pp. 242-247
-
-
Becker, M.L.1
Visser, L.E.2
van Schaik, R.H.3
Hofman, A.4
Uitterlinden, A.G.5
Stricker, B.H.6
-
60
-
-
62749133967
-
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study.
-
Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study. Diabetes 2009, 58:745-749.
-
(2009)
Diabetes
, vol.58
, pp. 745-749
-
-
Becker, M.L.1
Visser, L.E.2
van Schaik, R.H.N.3
Hofman, A.4
Uitterlinden, A.G.5
Stricker, B.H.C.6
-
61
-
-
77957601724
-
Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program.
-
Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, Saxena R, Fowler S, Shuldiner AR, Knowler WC, Altshuler D, Florez JC. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010, 59:2672-2681.
-
(2010)
Diabetes
, vol.59
, pp. 2672-2681
-
-
Jablonski, K.A.1
McAteer, J.B.2
de Bakker, P.I.3
Franks, P.W.4
Pollin, T.I.5
Hanson, R.L.6
Saxena, R.7
Fowler, S.8
Shuldiner, A.R.9
Knowler, W.C.10
Altshuler, D.11
Florez, J.C.12
-
62
-
-
0033624575
-
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.
-
Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000, 26:76-80.
-
(2000)
Nat Genet
, vol.26
, pp. 76-80
-
-
Altshuler, D.1
Hirschhorn, J.N.2
Klannemark, M.3
Lindgren, C.M.4
Vohl, M.C.5
Nemesh, J.6
Lane, C.R.7
Schaffner, S.F.8
Bolk, S.9
Brewer, C.10
Tuomi, T.11
Gaudet, D.12
Hudson, T.J.13
Daly, M.14
Groop, L.15
Lander, E.S.16
-
63
-
-
18344417084
-
Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.
-
Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003, 26:825-831.
-
(2003)
Diabetes Care
, vol.26
, pp. 825-831
-
-
Bluher, M.1
Lubben, G.2
Paschke, R.3
-
64
-
-
2542443906
-
Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-γ2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.
-
Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, Goico J, Shuldiner AR, Buchanan TA. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-γ2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004, 27:1365-1368.
-
(2004)
Diabetes Care
, vol.27
, pp. 1365-1368
-
-
Snitker, S.1
Watanabe, R.M.2
Ani, I.3
Xiang, A.H.4
Marroquin, A.5
Ochoa, C.6
Goico, J.7
Shuldiner, A.R.8
Buchanan, T.A.9
-
65
-
-
34147106645
-
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
-
The Diabetes Prevention Program Research Group
-
Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, Hamman RF, Knowler WC, Nathan DM, Altshuler D, . The Diabetes Prevention Program Research Group Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007, 92:1502-1509. The Diabetes Prevention Program Research Group.
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 1502-1509
-
-
Florez, J.C.1
Jablonski, K.A.2
Sun, M.W.3
Bayley, N.4
Kahn, S.E.5
Shamoon, H.6
Hamman, R.F.7
Knowler, W.C.8
Nathan, D.M.9
Altshuler, D.10
-
66
-
-
33644669582
-
Sequence variation in PPARG may underlie differential response to troglitazone.
-
Wolford JK, Yeatts KA, Dhanjal SK, Black MH, Xiang AH, Buchanan TA, Watanabe RM. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 2005, 54:3319-3325.
-
(2005)
Diabetes
, vol.54
, pp. 3319-3325
-
-
Wolford, J.K.1
Yeatts, K.A.2
Dhanjal, S.K.3
Black, M.H.4
Xiang, A.H.5
Buchanan, T.A.6
Watanabe, R.M.7
-
67
-
-
23444457610
-
Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes.
-
Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS, Lim SK, Nam CM, Lee HC. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005, 78:202-208.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 202-208
-
-
Kang, E.S.1
Park, S.Y.2
Kim, H.J.3
Kim, C.S.4
Ahn, C.W.5
Cha, B.S.6
Lim, S.K.7
Nam, C.M.8
Lee, H.C.9
-
68
-
-
33845515897
-
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
-
Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, Jetter A, Stehle S, Tsahuridu M, Meineke I, Brockmöller J, Fuhr U. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006, 80:657-667.
-
(2006)
Clin Pharmacol Ther
, vol.80
, pp. 657-667
-
-
Kirchheiner, J.1
Thomas, S.2
Bauer, S.3
Tomalik-Scharte, D.4
Hering, U.5
Doroshyenko, O.6
Jetter, A.7
Stehle, S.8
Tsahuridu, M.9
Meineke, I.10
Brockmöller, J.11
Fuhr, U.12
-
69
-
-
79251612707
-
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.
-
Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, Burch L, Carr F, Strange A, Freeman C, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Gray E, Hunt S, Jankowski J, Langford C, Markus HS, Mathew CG, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011, 43:117-120.
-
(2011)
Nat Genet
, vol.43
, pp. 117-120
-
-
Zhou, K.1
Bellenguez, C.2
Spencer, C.C.3
Bennett, A.J.4
Coleman, R.L.5
Tavendale, R.6
Hawley, S.A.7
Donnelly, L.A.8
Schofield, C.9
Groves, C.J.10
Burch, L.11
Carr, F.12
Strange, A.13
Freeman, C.14
Blackwell, J.M.15
Bramon, E.16
Brown, M.A.17
Casas, J.P.18
Corvin, A.19
Craddock, N.20
Deloukas, P.21
Dronov, S.22
Duncanson, A.23
Edkins, S.24
Gray, E.25
Hunt, S.26
Jankowski, J.27
Langford, C.28
Markus, H.S.29
Mathew, C.G.30
more..
-
70
-
-
79953216697
-
Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program.
-
Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, Hamman RF, Kahn SE, Haffner S, Meigs JB, Altshuler D, Knowler WC, Florez JC. Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes 2011, 60:1340-1348.
-
(2011)
Diabetes
, vol.60
, pp. 1340-1348
-
-
Hivert, M.F.1
Jablonski, K.A.2
Perreault, L.3
Saxena, R.4
McAteer, J.B.5
Franks, P.W.6
Hamman, R.F.7
Kahn, S.E.8
Haffner, S.9
Meigs, J.B.10
Altshuler, D.11
Knowler, W.C.12
Florez, J.C.13
-
72
-
-
0037116638
-
Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
-
Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287:360-372.
-
(2002)
JAMA
, vol.287
, pp. 360-372
-
-
Inzucchi, S.E.1
-
73
-
-
19244365650
-
Thiazolidinediones.
-
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
-
(2004)
N Engl J Med
, vol.351
, pp. 1106-1118
-
-
Yki-Jarvinen, H.1
-
74
-
-
33846006173
-
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
-
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
75
-
-
60449089649
-
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
-
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
-
(2009)
Diabetes Care
, vol.32
, pp. 193-203
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
Ferrannini, E.4
Holman, R.R.5
Sherwin, R.6
Zinman, B.7
-
76
-
-
57349160286
-
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
-
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
-
(2009)
Diabetologia
, vol.52
, pp. 17-30
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
Ferrannini, E.4
Holman, R.R.5
Sherwin, R.6
Zinman, B.7
-
77
-
-
75549091263
-
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
-
Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
-
(2009)
Endocr Pract
, vol.15
, pp. 540-559
-
-
Rodbard, H.W.1
Jellinger, P.S.2
Davidson, J.A.3
Einhorn, D.4
Garber, A.J.5
Grunberger, G.6
Handelsman, Y.7
Horton, E.S.8
Lebovitz, H.9
Levy, P.10
Moghissi, E.S.11
Schwartz, S.S.12
|